Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.

• Revenue in AUD (TTM)35.26k
• Net income in AUD-229.57m
• Incorporated1984
• Employees5.00

• Location
  Opthea LtdSuite 0403Level 4, 650 Chapel Street, South YarraMELBOURNE 3141AustraliaAUS
• Phone+61 39826-0399
• Fax+61 39824-0083
• Websitehttps://opthea.com/